Virtual screening to enrich hit lists from high-throughput screening: A case study on small-molecule inhibitors of angiogenin

Proteins: Structure, Function and Genetics

Volumn 50, Issue 1, 2003, Pages 81-93

  Jenkins, Jeremy L ^a   Kao, Richard Y T ^a   Shapiro, Robert ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenin; Consensus scoring; Enrichment; Enzyme inhibitor; False positives; High throughput screening; Ligand docking; Ribonuclease; Virtual screening

Indexed keywords

ANGIOGENIN; INHIBITOR PROTEIN;

ACCURACY; ANGIOGENESIS; ARTICLE; CALCULATION; DISSOCIATION CONSTANT; PRIORITY JOURNAL; SCORING SYSTEM; SCREENING;

EID: 0037235881     PISSN: 08873585     EISSN: None     Source Type: Journal    
DOI: 10.1002/prot.10270     Document Type: Article

References (79)

1. Hertzberg RP, Pope AJ. High-throughput screening: new technology for the 21st century. Curr Opin Chem Biol 2000;4:445-451.
2. Fernandes PB. Technological advances in high-throughput screening. Curr Opin Chem Biol 1998;2:597-603.
3. Ullmann D. Shifting the bottlenecks: HTS matures. Drug Discov Today (Suppl) 2001;6:S15-S16.
4. Wolcke J, Ullmann D. Miniaturized HTS technologies- uHTS. Drug Discov Today 2001;6:637-646.
5. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
6. Zhang JH, Chung TD, Oldenburg KR. Confirmation of primary active substances from high throughput screening of chemical and biological populations: a statistical approach and practical considerations. J Comb Chem 2000;2:258-265.
7. Cramer RD III, Patterson DE, Bunce JD. Recent advances in comparative molecular field analysis (CoMFA). Prog Clin Biol Res 1989;291:161-165.
8. Stanton DT, Morris TW, Roychoudhury S, Parker CN. Application of nearest-neighbor and cluster analysis in pharmaceutical lead discovery. J Chem InfComput Sci 1999;399:21-27.
9. Rusinko A, Farmen MW, Lambert CG, Brown PL, Young SS. Analysis of a large structure/biological activity data set using recursive partitioning. J Chem Inf Comput Sci 1999;39:1017-1026.
10. Gao H, Williams C, Labute P, Bajorath J. Binary quantitative structure-activity relationship (QSAR) analysis of estrogen receptor ligands. J Chem Inf Comput Sci 1999;39:164-168.
11. Hopfinger AJ, Duca JS. Extraction of pharmacophore information from high-throughput screens. Curr Opin Biotech 2000;11:97-103.
12. van Rhee AM, Stocker J, Printzenhoff D, Creech C, Wagoner PK, Spear KL. Retrospective analysis of an experimental high-throughput screening data set by recursive partitioning. J Comb Chem 2001;3:267-277.
13. Gedeck P, Willett P. Visual and computational analysis of structure-activity relationships in high-throughput screening data. Curr Opin Chem Biol 2001;5:389-395.
14. Tamura SY, Bacha PA, Gruver HS, Nutt RF. Data analysis of high-throughput screening results: application of multidomain clustering to the NCI anti-HIV data set. J Med Chem 2002;45: 3082-3093.
15. Rishton GM. Reactive compounds and in vitro false positives in HTS. Drug Discov Today 1997;2:382-384.
16. Earnshaw DL, Moore KJ, Greenwood CJ, Djaballah H, Jurewicz AJ, Murray KJ, Pope AJ. Time-resolved fluorescence energy transfer DNA helicase assays for high throughput screening. J Biomol Screen 1999;4:239-248.
17. Allen M, Reeves J, Mellor G. High throughput fluorescence polarization: a homogenous alternative to radioligand binding for cell surface receptors. J Biomol Screen 2000;5:63-69.
18. Kariv I, Cao H, Marvil PD, Bobkova EV, Bukhtiyarov YE, Yan TP, Patel U, Coudurier L, Chung TDY, Oldenburg KR. Identification of inhibitors of bacterial transcription/translation machinery utilizing a miniaturized 1536-well format screen. J Biomol Screen 2001;6:233-243.
19. Abagyan R, Totrov M. High-throughput docking for lead generation. Curr Opin Chem Biol 2001;5:375-382.
20. Halperin I, Buyong M, Wolfson H, Nussinov R. Principles of docking: an overview of search algorithms and a guide to scoring functions. Proteins 2002;47:409-443.
21. Welch W, Ruppert J, Jain AN. Hammerhead: fast, fully automated docking of flexible ligands to protein binding sites. Chem Biol 1996;3:449-462.
22. Charifson PS, Corkery JJ, Murcko MA, Walters WP. Consensus scoring: a method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J Med Chem 1999;42:5100-5109.
23. Knegtel RM, Wagener M. Efficacy and selectivity in flexible database docking. Proteins 1999;37:334-345.
24. Bissantz C, Folkers G, Rognan D. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J Med Chem 2000;43:4759-4767.
25. Stahl M, Rarey M. Detailed analysis of scoring functions for virtual screening. J Med Chem 2001;44:1035-1042.
26. Muegge I, Martin YC, Hajduk PJ, Fesik SW. Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein. J Med Chem 1999;42:2498 -2503.
27. Joseph-McCarthy D. Computational approaches to structure-based ligand design. Pharmacol Ther 1999;84:179-191.
28. Schneider G, Bohm HJ. Virtual screening and fast automated docking methods. Drug Discov Today 2002;7:64-70.
29. Kearsley SK, Sallamack S, Fluder EM, Andose JD, Mosley RT, Sheridan RP. Chemical similarity using physiochemical property descriptors. J Chem Inf Comput Sci 1996;36:118-127.
30. Ginn CMR, Turner DB, Willett P. Similarity searching in files of three-dimensional chemical structures: evaluation of the EVA descriptor and combination of rankings using data fusion. J Chem Inf Comput Sci 1997;37:23-27.
31. Gohlke H, Klebe G. Statistical potentials and scoring functions applied to protein-ligand binding. Curr Opin Struct Biol 2001;11:231-235.
32. Terp GE, Johansen BN, Christensen IT, Jorgensen FS. A new concept for multidimensional selection of ligand conformations (MultiSelect) and multidimensional scoring (MultiScore) of protein- ligand binding affinities. J Med Chem 2001;44:2333-2343.
33. Wang R, Wang S. How does consensus scoring work for virtual library screening? An idealized computer experiment. J Chem Inf Comput Sci 2001;41:1422-1426.
34. Clark RD, Strizhev A, Leonard JM, Blake JF, Matthew JB. Consensus scoring for ligand/protein interactions. J Mol Graph Model 2002;20:281-295.
35. Paul N, Rognan D. ConsDock: a new program for the consensus analysis of protein-ligand interactions. Proteins 2002;47:521-533.
36. Good AC, Krystek SR, Mason JS. High-throughput and virtual screening: core lead discovery technologies move towards integration. Drug Discov Today 2000;5:61-69.
37. Stahura FL, Xue L, Godden JW, Bajorath J. Methods for compound selection focused on hits and application in drug discovery. J Mol Graph Model 2002;20:439-446.
38. Poulain R, Horvath D, Bonnet B, Eckhoff C, Chapelain B, Bodinier MC, Deprez B. From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands. J Med Chem 2001;44:3378-3390.
39. Diller DJ, Merz KM Jr. High throughput docking for library design and library prioritization. Proteins 2001;43:113-124.
40. Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 1985;24:5480-5486.
41. Li D, Bell J, Brown A, Berry CL. The observation of angiogenin and basic fibroblast growth factor gene expression in human colonic adenocarcinomas, gastric adenocarcinomas, and hepatocellular carcinomas. J Pathol 1994;172:171-175.
42. Shimoyama S, Gansauge F, Gansauge S, Negri G, Oohara T, Beger HG. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Cancer Res 1996;56:2703-2706.
43. Hartmann A, Kunz M, Kostlin S, Gillitzer R, Toksoy A, Brocker EB, Klein CE. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res 1999;59:1578-1583.
44. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence. Cancer 1999;86:316-324.
45. Etoh T, Shibuta K, Barnard GF, Kitano S, Mori M. Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. Clin Cancer Res 2000;6:3545-3551.
46. Olson KA, French TC, Vallee BL, Fett JW. A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice. Cancer Res 1994;54:4576-4579.
47. Olson KA, Fett JW, French TC, Key ME, Vallee BL. Angiogenin antagonists prevent tumor growth in vivo. Proc Natl Acad Sci USA 1995;92:442-446.
48. Olson KA, Byers HR, Key ME, Fett JW. Prevention of human prostate tumor metastasis in athymic mice by antisense targeting of human angiogenin. Clin Cancer Res 2001;7:3598-3605.
49. Strydom DJ, Fett JW, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL. Amino acid sequence of human tumor derived angiogenin. Biochemistry 1985;24:5486-5494.
50. Acharya KR, Shapiro R, Allen SC, Riordan JF, Vallee BL. Crystal structure of human angiogenin reveals the structural basis for its functional divergence from ribonuclease. Proc Natl Acad Sci USA 1994;91:2915-2919.
51. Leonidas DD, Shapiro R, Allen SC, Subbarao GV, Veluraja K, Acharya KR. Refined crystal structures of native human angiogenin and two active site variants: implications for the unique functional properties of an enzyme involved in neovascularisation during tumour growth. J Mol Biol 1999;285:1209-1233.
52. Shapiro R, Riordan JF, Vallee BL. Characteristic ribonucleolytic activity of human angiogenin. Biochemistry 1986;25:3527-3532.
53. Shapiro R, Vallee BL. Site-directed mutagenesis of histidine-13 and histidine-114 of human angiogenin. Alanine derivatives inhibit angiogenin-induced angiogenesis. Biochemistry 1989;28:7401-7408.
54. Shapiro R, Fox EA, Riordan JF. Role of lysines in human angiogenin: chemical modification and site-directed mutagenesis. Biochemistry 1989;28:1726-1732.
55. Russo N, Acharya KR, Vallee BL, Shapiro R. A combined kinetic and modeling study of the catalytic center subsites of human angiogenin. Proc Natl Acad Sci USA 1996;93:804-808.
56. Russo A, Acharya KR, Shapiro R. Small molecule inhibitors of RNase A and related enzymes. Methods Enzymol 2001;341:629-648.
57. Kelemen BR, Klink TA, Behlke MA, Eubanks SR, Leland PA, Raines RT. Hypersensitive substrate for ribonucleases. Nucleic Acids Res 1999;27:3696-3701.
58. Kao RYT, Jenkins JL, Olson KA, Key ME, Fett JW, Shapiro R. A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity. Proc Natl Acad Sci USA 2002;99:10066-10071.
59. Walters P, Stahl M. Babel v.1.6. U. of Arizona; 1996. WWW address: http://smog.com/chem/babel.
60. Leonidas DD, Chavali GB, Jardine AM, Li S, Shapiro R, Acharya KR. Binding of phosphate and pyrophosphate ions at the active site of human angiogenin as revealed by X-ray crystallography. Protein Sci 2001;10:1669-1676.
61. Hart TN, Ness SR, Read RJ. Critical evaluation of the research docking program for the CASP2 challenge. Proteins 1997;Suppl:205-209.
62. Bohm HJ. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J Comput Aid Mol Des 1994;8:243-256.
63. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727-748.
64. Ajay, Murcko MA, Stouten PFW. Recent advances in the prediction of binding free energy. In: Charifson PS, editor. Practical application of computer-aided drug design. New York: Marcel Dekker, Inc.; 1997;355-410.
65. Bohm HJ. Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de novo design or 3D database search programs. J Comput Aid Mol Des 1998;12:309-323.
66. Guner OF, Henry DR. Metric for analyzing hit lists and pharmacophores. In: Guner OF, editor. Pharmacophore perception, development, and use in drug design. La Jolla: IUL Biotechnology Series; 2000. p 193-210.
67. McGovern SL, Caselli E, Grigorieff N, Shoichet BK. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem 2002;45:1712-1722.
68. Wu P, Brasseur M, Schindler U. A high-throughput STAT binding assay using fluorescence polarization. Anal Biochem 1997;249:29-36.
69. Mellor GW, Burden MN, Preaudat M, Joseph Y, Cooksley SB, Ellis JH, Banks MN. Development of a CD28/CD86 (B7-2) binding assay for high throughput screening by homogenous time-resolved fluorescence. J Biomol Screen 1998;3:91-99.
70. McMartin C, Bohacek RS. QXP: powerful, rapid computer algorithms for structure-based drug design. J Comput Aid Mol Des 1997;11:333-344.
71. Broughton HB. A method for including protein flexibility in protein-ligand docking: improving tools for database mining and virtual screening. J Mol Graph Model 2000;18:247-257.
72. Claussen H, Buning C, Rarey M, Lengauer T. FlexE: efficient molecular docking considering protein structure variations. J Mol Biol 2001;308:377-395.
73. Schnecke V, Swanson CA, Getzoff ED, Tainer JA, Kuhn LA. Screening a peptidyl database for potential ligands to proteins with side-chain flexibility. Proteins 1998;33:74-87.
74. Osterberg F, Morris GM, Sanner MF, Olson AJ, Goodsell DS. Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in AutoDock. Proteins 2002;46:34-40.
75. Russo N, Shapiro R, Acharya KR, Riordan JF, Vallee BL. Role of glutamine-117 in the ribonucleolytic activity of human angiogenin. Proc Natl Acad Sci USA 1994;91:2920-2924.
76. DesJarlais RL, Seibel GL, Kuntz ID, Furth PS, Alvarez JC, Ortiz de Montellano PR, DeCamp DL, Babe LM, Craik CS. Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. Proc Natl Acad Sci USA 1990;87:6644-6648.
77. Rutenber E, Fauman EB, Keenan RJ, Fong S, Furth PS, Ortiz de Montellano PR, Meng E, Kuntz ID, DeCamp DL, Salto R, et al. Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design. J Biol Chem 1993;268:15343-15346.
78. Fejzo J, Lepre CA, Peng JW, Bemis GW, Ajay, Murcko MA, Moore JM. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chem Biol 1999;6:755-769.
79. Blundell TL, Jhoit H, Abell C. High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Discov 2002;1.